袁月;卢增辉;祝晨蔯;郑志华;林朝展;
YUAN Yue;LU Zenghui;ZHU Chenchen;ZHENG Zhihua;LIN Chaozhan;School of Pharmaceutical Sciences,Guangzhou University of Chinese Medicine;Guang Dong Pharmaceutical Association;

• 1:广州中医药大学中药学院
• 2:广东省药学会

摘要(Abstract)：

目的采用网络药理学的方法,筛选荷丹片组方的活性成分和与高脂血症疾病相关的作用靶点,通过生物过程与通路富集预测其作用机制,从而获得荷丹片与他汀类药物协同作用的依据。方法利用中药系统药理学分析平台(TCMSP,https:∥tcmspw.com/tcmsp.php)等数据库及文献筛选荷丹片的活性成分及靶点,利用Geen Card数据库(https:∥www.genecards.org/)获取高脂血症疾病靶点,筛选出荷丹片降脂的主要靶点,通过Cytoscape软件和STRING数据库进行作用靶点的蛋白互作分析、生物功能分析和通路富集,预测荷丹片降脂作用的机制,并根据预测得到的降脂机制,探讨荷丹片与他汀类药物的协同作用。结果经过筛选,共获得荷丹片的活性成分163个,在荷丹片的成分靶点与高脂血症的疾病靶点两者间取得交集,获得荷丹片对高脂血症的潜在作用靶点52个,蛋白相互作用网络分析表明,AKT1、ALB、INS、GAPDH和IL6可能是荷丹片治疗高脂血症的关键靶点,KEGG通路富集表明在荷丹片涉及的通路中,与疾病的治疗相关性较大的通路有脂肪细胞因子信号通路、非酒精性脂肪肝信号通路、胰岛素抵抗和胰高血糖素信号通路、花生四烯酸代谢通路和脂肪酸生物合成等。这与他汀类药物降脂作用的机制相似,证明荷丹片与他汀类药物在降脂作用上具有一致的作用通路和靶点,为其协同作用提供了可能。结论研究预测了荷丹片的降脂机制,体现了中药多成分、多靶点的作用特点,荷丹片能够有效的调节机体内脂肪酸生物过程、糖代谢过程和脂质代谢过程,为荷丹片与他汀类药物协同作用增加降脂疗效提供了依据。
OBJECTIVE Based on the network pharmacology,the active compounds and targets related to hyperlipidemia of HeDan tablet were searched,and the lipid-lowering mechanism were predicted by biological process and pathway enrichment,to provide the theory basis of synergistic lipid-lowering effect of HeDan tablet and statins. METHODS The active constituents and targets were acquired from online databases including TCMSP,and the main disease targets were obtained from OMIM online database. The effective lipid-lowering targets in HeDan tablet were screened,and the Protein-Protein interaction,biological process analysis and pathway enrichment were constructed by Cytoscape and String online database. The lipid lowering mechanism of HeDan tablet was proved and the possibility of synergism between HeDan tablet and statins were explored. RESULTS 163 active compounds of HeDan tablet and 52 targets related to hyperlipidemia were acquired from screening. Protein-Protein interaction network showed that AKT1,ALB,INS,GAPDH and IL6 were the key targets totreat hyperlipidemia. KEGG pathway enrichment showed that adipocytokine signaling pathway,non-alcoholic fatty liver signaling pathway,insulin resistance and glucagon signaling pathway,arachidonic acid metabolism pathway and fatty acid biosynthesis were significantly associated with the treatment of hyperlipidemia,similar to statins. This work proved the synergistic lipid-lowering effect of HeDan tablet and statins. CONCLUSION The study predicted the lipid-lowering mechanism of HeDan tablet based on network pharmacology,reflected the characteristics of multi-component and multi-target of traditional Chinese medicine,provided theoretical basis for the synergistic lipid-lowering effect between HeDan tablet and statin.

关键词(KeyWords)： 荷丹片;网络药理学;高脂血症;协同作用
HeDan tablet;network pharmacology;hyperlipidemia;synergistic effect

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 袁月;卢增辉;祝晨蔯;郑志华;林朝展;
YUAN Yue;LU Zenghui;ZHU Chenchen;ZHENG Zhihua;LIN Chaozhan;School of Pharmaceutical Sciences,Guangzhou University of Chinese Medicine;Guang Dong Pharmaceutical Association;

Email:

DOI:

参考文献(References)：

• [1]Karr S.Epidemiology and management of hyperlipidemia[J].Am JManag Care,2017,23(9):139-148．
• [2]Farnier M,Davignon J.Current and future treatment of hyperlipidemia:the role of statins[J].The American Journal of Cardiology,1998,82(4B):3J-10J．
• [3]圣洪平，许敏芳，徐俊良．荷丹片治疗高脂血症疗效观察与中医辨证分型研究[J]．中国社区医师，2016,32(35):125-126．
• [4]潘美香，孙斌．荷丹片临床应用进展[J]．中国妇幼健康研究，2016,27(S1):296-297．
• [5]杨福梅．阿托伐他汀钙片联合荷丹片治疗混合型高脂血症的疗效观察[J]．云南中医中药杂志，2017,38(12):31-32．
• [6]包丹丹，宋宗良，赵峰，等．中成药联合他汀类治疗高脂血症的Meta分析[J]．世界中医药，2020,15(13):1946-1952．
• [7]范英丽，朱叶，尹德辉．荷丹片联合阿托伐他汀治疗中青年血脂异常35例[J]．医药导报，2014,33(8):1029-1031．
• [8]Lee A Y,Park W,Kang T W,et al.Network pharmacology-based prediction of active compounds and molecular targets in Yijin-Tang acting on hyperlipidaemia and atherosclerosis[J].J Ethnopharmacol,2018,221:151-159．
• [9]钟华，仇静文，吴鸿飞，等．基于网络药理学的瓜蒌-薤白药对抗高脂血症的作用机制[J]．中国药理学与毒理学杂志，2019,33(9):731-732．
• [10]王珊珊，黄楚龙，黎芳，等．复方熊胆滴眼液治疗急性细菌性结膜炎作用及其机制的网络药理学分析[J]．广东药科大学学报，2020,36(1):78-83．
• [11]张泽鑫，吴汶丰，谢丹，等．基于网络药理学联合GEO芯片分析干姜黄芩黄连人参汤治疗2型糖尿病的机理和分子靶点[J]．广东药科大学学报，2020,36(3):361-368．
• [12]张彦琼，李梢．网络药理学与中医药现代研究的若干进展[J]．中国药理学与毒理学杂志，2015,29(6):883-892．
• [13]Endo A,Hasumi K.HMG-Co A reductase inhibitors[J].Nat Prod Rep,1993,10(6):541-550．
• [14]Friesen J A,Rodwell V W.The 3-hydroxy-3-methylglutaryl coenzyme-A(HMG-Co A) reductases[J].Genome Biol,2004,5 (11):248．
• [15]Bansal A B,Cassagnol M.HMG-Co A Reductase Inhibitors[M].Treasure Island(FL):Stat Pearls Publishing,2020．
• [16]吴冬梅，张晓东．荷叶水提物对3T3-L1前体脂肪细胞增殖、凋亡及前体脂肪细胞、成熟脂肪细胞IL-6 mRNA、TNF-αmRNA的影响[J]．中医研究，2020,33(9):57-60．
• [17]范婷婷，法鲁克，方芳，等．荷叶总生物碱降脂减肥作用的体内外试验[J]．浙江大学学报(农业与生命科学版)，2013,39(2):141-148．
• [18]Zhang C,Deng J,Liu D,et al.Nuciferine ameliorates hepatic steatosis in high-fat diet/streptozocin-induced diabetic mice through a PPARα/PPARγcoactivator-1αpathway[J].Br J Pharmacol,2018,175(22):4218-4228．
• [19]Nguyen K H,Ta T N,Pham T H,et al.Nuciferine stimulates insulin secretion from beta cells-an in vitro comparison with glibenclamide[J].J Ethnopharmacol,2012,142(2):488-495．
• [20]Ma C,Li G,He Y,et al.Pronuciferine and nuciferine inhibit lipogenesis in 3T3-L1 adipocytes by activating the AMPK signaling pathway[J].Life Sci,2015,136:120-125．
• [21]Ren J,Fu L,Nile S H,et al.Salvia miltiorrhiza in Treating Cardiovascular Diseases:A Review on Its Pharmacological and Clinical Applications[J].Front Pharmacol,2019,10:753．
• [22]张诗军，陈泽雄，林佑武，等．复方丹参滴丸治疗痰瘀型高脂血症的临床研究[J]．中国中药杂志，2007,32(5):440-443．
• [23]王智，侯立强，王爽，等．复方丹参降脂饮降血脂作用及作用机制的研究[J]．中华中医药学刊，2013,31(12):2659-2661．
• [24]朱小晓．降脂平治疗高脂血症48例临床观察[J]．湖南中医杂志，1996,12(5):4．
• [25]张卫斌．补肾活血化痰法对动脉粥样硬化斑块炎性因子的干预研究[D]．广州:广州中医药大学，2010．
• [26]封若雨，朱新宇，张苗苗．近五年山楂药理作用研究进展[J]．中国中医基础医学杂志，2019,25(5):715-718．
• [27]江震宇．山楂降血糖、降血脂活性成分及机理初探[D]．金华:浙江师范大学，2019．
• [28]杨莺，姚新月，李海波．山楂通过肠道菌群治疗脂质代谢异常的实验[J/OL]．中华中医药学刊:1-8[2020-09-17].http:∥kns.cnki.net/kcms/detail/21.1546.r.20200303.1759.002.html．
• [29]Niswender K D.Basal insulin:physiology,pharmacology,and clinical implications[J].Postgrad Med,2011,123(4):17-26．
• [30]Friedman S L,Neuschwander-Tetri B A,Rinella M,et al.Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922．
• [31]van den Berg E H,Wolters A A B,Dullaart R P F,et al.Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk,a population-based study[J].Liver international:Official Journal of the International Association for the Study of the Liver,2019,39(7):1343-1354．
• [32]Bansal A B,Cassagnol M.HMG-Co A Reductase Inhibitors[M].Treasure Island(FL):Stat Pearls Publishing,2020．
• [33]Kothari S,Dhami-Shah H.Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease[J].Journal of Clinical and Experimental Hepatology,2019,9(6):723-730．
• [34]Liu S,Jing F,Yu C,et al.AICAR-Induced Activation of AMPK Inhibits TSH/SREBP-2/HMGCR Pathway in Liver[J].PLo S One,2015,10(5):e0124951.